Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2006

01-12-2006 | Original

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma

A single institution's experience

Authors: Faruk Tas, Sidika Kurul, Hakan Camlica, Erkan Topuz

Published in: Medical Oncology | Issue 4/2006

Login to get access
Metadata
Title
Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma
A single institution's experience
Authors
Faruk Tas
Sidika Kurul
Hakan Camlica
Erkan Topuz
Publication date
01-12-2006
Publisher
Humana Press
Published in
Medical Oncology / Issue 4/2006
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1385/MO:23:4:471

Other articles of this Issue 4/2006

Medical Oncology 4/2006 Go to the issue

Original Article

Mid-course thoracic radiotherapy with cisplatin-etoposide chemotherapy in limited-stage small-cell lung cancer

Original Article

Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer

Original

Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma

Review

Bone diesease in multiple myeloma

Original Article

Predictive value of prognostic indices in patients with follicular lymphomas

Original

Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits